These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35063632)
1. BOPPY-based novel fluorescent dopamine D Elek M; Dubiel M; Mayer L; Zivkovic A; Müller TJJ; Stark H Bioorg Med Chem Lett; 2022 Mar; 59():128573. PubMed ID: 35063632 [TBL] [Abstract][Full Text] [Related]
3. Aromatic linker variations in novel dopamine D Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025 [TBL] [Abstract][Full Text] [Related]
4. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, in silico, and in vitro studies of novel dopamine D Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands. Zhou B; Hong KH; Ji M; Cai J Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404 [TBL] [Abstract][Full Text] [Related]
7. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
9. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986 [TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094 [TBL] [Abstract][Full Text] [Related]
11. Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D Battiti FO; Zaidi SA; Katritch V; Newman AH; Bonifazi A J Med Chem; 2021 Nov; 64(21):16088-16105. PubMed ID: 34699207 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands. Ortega R; Raviña E; Masaguer CF; Areias F; Brea J; Loza MI; López L; Selent J; Pastor M; Sanz F Bioorg Med Chem Lett; 2009 Mar; 19(6):1773-8. PubMed ID: 19217777 [TBL] [Abstract][Full Text] [Related]
14. Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model. Sukalovic V; Soskic V; Sencanski M; Andric D; Kostic-Rajacic S J Mol Model; 2013 Apr; 19(4):1751-62. PubMed ID: 23300056 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938 [TBL] [Abstract][Full Text] [Related]
16. Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D Appiah-Kubi P; Olotu FA; Soliman MES J Mol Recognit; 2021 May; 34(5):e2885. PubMed ID: 33401335 [TBL] [Abstract][Full Text] [Related]
17. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551 [TBL] [Abstract][Full Text] [Related]
18. Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. Wang Q; Mach RH; Luedtke RR; Reichert DE J Chem Inf Model; 2010 Nov; 50(11):1970-85. PubMed ID: 20936866 [TBL] [Abstract][Full Text] [Related]
19. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands. Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201 [TBL] [Abstract][Full Text] [Related]
20. Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model. Brown DA; Kharkar PS; Parrington I; Reith ME; Dutta AK J Med Chem; 2008 Dec; 51(24):7806-19. PubMed ID: 19053758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]